It is the most common form of cancer that has claimed more than 8,000,000 lives in 2012. Each year, 14 million cases are reported. There are many types of it and no cure is yet.

Part of the problem with finding a cure for cancer lies in the fact that although scientists thought they knew the basics of how it works, it has only been in the past decade that they have been able better understand this deadly disease. Cancer is more complicated than initially thought.

One company believes it might have the solution. Propanc Health Group Corporation(OTCB : PPCH), is focused on the development of treatments for patients with solid tumors like pancreatic, ovarian and colorectal cancers.

The company was able to file four patent applications up until recently for PRP, its lead product. This proenzyme anti-cancer compound targets cancer stem cell elimination while protecting normal stem cells. Two more patents have been added to the company’s portfolio.

“I have no doubt PRP represents a new therapeutic drug class with significant potential [because] when confirming PRP’s effectiveness across a broad range of cancers, we also confirmed a synergistic response between the two proenzymes to the majority of cancer cell lines tested,”Prof. Julian Kenyon is Propane’s Chief Scientist Officer. “We also noticed that for some cancer types, multiple combinations of the two proenzymes proved to be effective.”

Recently, Propanc met with the Medicines and Healthcare Products Regulatory Agency to discuss formal preclinical and clinical development for PRP. Additionally, Propanc stated it will apply for orphan drug status for pancreatic and/or ovarian cancers in Europe as well as the US in the near term.

This biotech company has attracted investors with the addition of five patents. Propanc received over $1 million in March 2016 from an institutional investor to help it accelerate its pre-clinical activities. Its total amount is now approximately $3.6million.

Global Analyst reports predicts that by 2020, the world market for pancreatic cancer, ovarian, and colorectal cancers will be more than $12 Billion.

Visit this site to learn more